tetano
Editor, Senior Moderator
Antimicrob Agents Chemother. 2015 Sep 14. pii: AAC.01885-15. [Epub ahead of print]
[h=1]Assessment of antiviral properties of Peramivir against H7N9 avian influenza virus in an experimental mouse model.[/h] Farooqui A[SUP]1[/SUP], Huang L[SUP]2[/SUP], Wu S[SUP]3[/SUP], Cai Y[SUP]4[/SUP], Su M[SUP]5[/SUP], Lin P[SUP]2[/SUP], Chen W[SUP]3[/SUP], Fang X[SUP]3[/SUP], Zhang L[SUP]6[/SUP], Liu Y[SUP]6[/SUP], Zeng T[SUP]6[/SUP], Paquette SG[SUP]7[/SUP], Khan A[SUP]8[/SUP], Kelvin AA[SUP]9[/SUP], Kelvin DJ[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The H7N9 influenza virus causes severe form of disease in humans. Neuraminidase inhibitors including oral oseltamivir and injectable peramivir are the first choices of antiviral treatment for such cases, however the clinical efficacy of these drugs is questionable. Animal experimental models are essential to understand the viral replication kinetics under the selective pressure of antiviral agents. This study, for the first time demonstrates the antiviral activity of peramivir in mouse model of H7N9 avian influenza virus infection. The data shows that repeated administration of 30mg/kg peramivir successfully eradicates virus from respiratory tract and extrapulomnary tissues during the acute response and prevents clinical signs of the disease including neuropathy and eventually protects mice against lethal H7N9 influenza infection. The early treatment with peramivir is found to be associated with better disease outcome.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 26369969 [PubMed - as supplied by publisher]
[h=1]Assessment of antiviral properties of Peramivir against H7N9 avian influenza virus in an experimental mouse model.[/h] Farooqui A[SUP]1[/SUP], Huang L[SUP]2[/SUP], Wu S[SUP]3[/SUP], Cai Y[SUP]4[/SUP], Su M[SUP]5[/SUP], Lin P[SUP]2[/SUP], Chen W[SUP]3[/SUP], Fang X[SUP]3[/SUP], Zhang L[SUP]6[/SUP], Liu Y[SUP]6[/SUP], Zeng T[SUP]6[/SUP], Paquette SG[SUP]7[/SUP], Khan A[SUP]8[/SUP], Kelvin AA[SUP]9[/SUP], Kelvin DJ[SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The H7N9 influenza virus causes severe form of disease in humans. Neuraminidase inhibitors including oral oseltamivir and injectable peramivir are the first choices of antiviral treatment for such cases, however the clinical efficacy of these drugs is questionable. Animal experimental models are essential to understand the viral replication kinetics under the selective pressure of antiviral agents. This study, for the first time demonstrates the antiviral activity of peramivir in mouse model of H7N9 avian influenza virus infection. The data shows that repeated administration of 30mg/kg peramivir successfully eradicates virus from respiratory tract and extrapulomnary tissues during the acute response and prevents clinical signs of the disease including neuropathy and eventually protects mice against lethal H7N9 influenza infection. The early treatment with peramivir is found to be associated with better disease outcome.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 26369969 [PubMed - as supplied by publisher]